This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read UroGen Pharma’s 8K filing here.
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
- Five stocks we like better than UroGen Pharma
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- DuPont Is the Unexpected Benefactor of the AI Boom
- Canada Bond Market Holiday: How to Invest and Trade
- Post-Election Manufacturing Boom: 3 Stocks Analysts Are Eyeing
